Eva Yazhari, venture capitalist and mother of two, shares a powerful message for female founders: you define what success looks like. In this heartfelt conversation, she reflects on her 14-year journey building Beyond Capital Ventures while raising her children—proving that motherhood and entrepreneurship can coexist beautifully. #Leadership #Motherhood #WomenInBusiness #VentureCapital…
How do you build investor trust when your fund is brand new? Eva Yazhari, Founder of Beyond Capital Ventures, shares why she focused on institutional quality from day one. Drawing lessons from her early career on Wall Street during the Bernie Madoff era, she explains how transparency, compliance, and operational…
Eva Yazhari’s mission is simple but radical: to change how people think about money. Her book, The Good Your Money Can Do, has inspired readers to see wealth not just as power—but as potential. In this conversation, Eva shares how her framework has helped people move their money into impact-driven…
What separates consistent performers from lucky traders? Eva Yazhari, Founder of Beyond Capital Ventures, breaks down the traits shared by top investors like Bill Ackman and others who consistently win in high-stakes markets. Drawing from her experience during the Global Financial Crisis, Eva reveals how discipline, data-driven conviction, and self-awareness…
To Dr. Nadine Burke Harris, the best way to deal with situations like that is to learn how your body operates under the circumstances and optimez your understanding of the situation. It’s not easy, but it will help you prevent long term issues that could eventually put your health at…
Dr. Nadine Burke Harris observes that no community is free from danger, but after speaking to several world leaders she realized how she could create strenghts from weak spots that impact everyone’s lives.
Dr. Nadine Burke recalls the time she first met with John Miller and why she decided to support his work.
Dr. Nadine analyzes how early detection of stressful or traumatic events in childhood can rewire the body’s response and impact a person’s overall health.
Jamie Rhode breaks down one of venture capital’s core realities—the Power Law. In this short, she compares the dynamic of blockbuster startups to the movie industry: a handful of “Avengers-level” hits drive nearly all the profits. She explains how this asymmetry defines the economics of venture investing and why identifying…
Jamie Rhode reframes volatility—not as risk, but as opportunity. She explains why early-stage venture capital rewards those who can handle variance, play the long game, and resist reacting to short-term noise. Drawing on data from decades of performance, Jamie reveals that nearly half of a fund’s total returns come in…
Jamie Rhode shares how Screendoor achieves consistency in an unpredictable industry. By combining data-driven analysis with experience from her days at Bloomberg and Verdis, she explains how to balance exposure across 20+ fund managers—without losing focus or agility. #Leadership #VentureCapital #Investing #Entrepreneurship #PortfolioDesign #JamieRhode #InnovationAndLeadership
Jamie Rhode breaks down one of venture capital’s most misunderstood topics: the difference between alpha and beta. She explains how the “beta of venture” — the market’s average 3X net return over 40 years — is already impressive, but the real magic happens when investors find alpha, or the performance…
Julie Wainwright explains the deeper psychology of luxury branding. Luxury is more than function—it’s romance, aspiration, and identity. Brands invest heavily in image, weaving a story that makes their products desirable. But as Julie points out, the products themselves must also deliver: exceptional quality, timeless design, and in many cases,…
Julie Wainwright shares the scrappy early days of building The RealReal. At launch, supply was the biggest challenge—home parties and friends-of-friends were not scalable. Julie tried a stylist program in Los Angeles, pitching directly to agencies and stylists, but early results were underwhelming. Then came a turning point: a celebrity…
Julie Wainwright shares powerful insights for founders trying to break through the “hundreds of millions” ceiling. She explains why understanding your total available market is the foundation—if the market is truly massive, your current revenue may only scratch the surface. But identifying your true lever—supply, demand, or technology—becomes the key…
Julie Wainwright walks us through the story of The RealReal — the first company to bring authenticated luxury resale online at scale. From fine jewelry to handbags to watches, she explains how the platform created a new category by taking full possession of items, guaranteeing authentication, and serving millions of…
What if homes could be designed not just with technology—but around the emotions and experiences that matter most to families? Glenn Gow explains how AI can capture the details that make each house feel special, from favorite music and room layouts to pool temperatures and scents. With AI, the next…
Glenn Gow, known as The CEO Success Coach, explains how he pushes leaders to embrace AI in ways that go beyond the hype. For him, it’s about three critical layers: adopting AI in daily operations, maximizing it in software development, and embedding it into core offerings. CEOs who hesitate risk…
Glenn Gow shares what happens when CEOs plateau at hundreds of millions and want to push past the billion-dollar mark. His first step isn’t about strategy or scale—it’s about asking the question why. Without clarity on deeper motivations, any plan for growth risks being hollow.
Glenn Gow shares his remarkable journey from running a Silicon Valley consulting firm that served Apple, Google, Meta, and Microsoft, to becoming a venture capitalist and ultimately a CEO coach. His transition was fueled by a passion for helping leaders grow and by recognizing the power of adding value in…
Serina Therapeutics is preparing to launch a critical early-stage clinical trial for their apomorphine-based therapy. By late Q1 or early Q2 next year, they expect to know if they’ve eliminated the painful skin reactions that have plagued existing therapies—a massive milestone for both patients and the biotech community. #InnovationAndLeadership #ParkinsonsResearch…
Current therapies for Parkinson’s patients facing motor fluctuations are far from ideal—infusion pumps that irritate the skin and limit quality of life. Serina Therapeutics is taking a bold step forward by reimagining apomorphine delivery through its unique polymer platform. The result? A shot at delivering consistent, long-lasting relief with fewer…
Multiple Shots on Goal in Biotech #shorts Biotech is often described as a “binary bet”—one product, one chance, and if the trial data doesn’t hold, it all collapses. But Serina Therapeutics is rewriting that narrative. With a platform spanning multiple therapeutic areas, they are building not just one pipeline, but…
What if one medical breakthrough could transform millions of lives—and create companies valued in the trillions? Steve Ledger and Simba Gill reveal why Serina Therapeutics is positioned to make late-stage Parkinson’s and other devastating diseases more treatable, potentially reshaping healthcare and financial markets alike. #InnovationAndLeadership #Biotech #HealthcareInnovation #ParkinsonsResearch #SerinaTherapeutics #FlagshipPioneering…
